Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “CLAUDICATION”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,009 records · Page 56Linked to original sources
PubMedDate not supplied

High prevalence of coronary heart disease in patients with intermittent claudication. A preliminary report.

Twenty-five men aged 53-70 years, with stable intermittent claudication and similar symptoms and walking distance, were investigated with myocardial scintigraphy, duplex ultrasonography of carotid arteries and femoral angiography. Each patient was scored according to the degree of stenosis in the popliteal trifurcation and the aortoiliac and carotid arteries. Eighteen of the 25 men had coronary heart disease, which was clinically evident in nine cases and scintigraphically demonstrated in 17/24. Ischemia or infarction without clinical manifestation was located in the atrio-ventricular septal region in all nine cases. Eight of the 25 patients were shown to have carotid lesions. Significant correlation was found between lesions in the trifurcation and in the carotid arteries, but not between aortoiliac and carotid lesions. Trifurcational disease was a somewhat weaker marker for coronary heart disease. The high prevalence of coronary heart disease is noteworthy, especially the septal pathology, and further studies on the clinical significance of the findings appear to be urgently required.

Aged↗
PubMed1988

Intermittent intraarterial infusion therapy with PGE1 in patients with severe claudication--results of a randomized prospective double blind study.

In a randomized prospective double blind study, intraarterial infusion therapy with prostaglandin E1 (PGE) was tested against infusion therapy with energy rich phosphates (ERP) in 40 patients with severe claudication. During the treatment period of three weeks, a significant increase of the painfree (PWD) and maximal walking distance (MWD) was observed. The improvement of PWD was of clinical relevance (PGE: 60----195 m; ERP: 69----170 m; p less than 0.001) and persisted during a 36 week post treatment observation period. The differences between the two drugs were not significant but showed a tendency in favour of the PGE therapy.

Alprostadil↗
PubMed1979

Intermittent claudication--epidemiology and natural history.

Epidemiological information on the prevalence, incidence and natural history of intermittent claudication and peripheral vascular disease is limited, partially by the limitation of techniques of their study. The available data from the literature are review and supplemented by results from an on-going survey the ankle blood pressure measurement with Doppler ultrasound.

Adult↗
PubMed1979

Intermittent claudication--pathophysiological considerations.

Intermittent claudication is a non-pathognomic symptom elicited by an inbalance between the metabolic demands of the exercising skeletal muscle and its blood supply. In normal conditions hyperemia to the working muscles will be impaired during the exercise by mechanical compression of the microvessels. The resulting anaerobic metabolism will cause further vasodilatation. Both phenomena (exercise and reactive hyperemia) contribute to a maximal increase in local blood flow as soon as the exercise is stopped. If the local circulation is impaired by occluding arterial disease (eventually complicated by aggravating factors) the tolerance to skeletal work is lowered and the circulatory reserves are entirely exhausted as demonstrated by the ischemic exercise-test. In the case of a major obstruction and poor collateralisation, a "steel phenomenon" may occur. The pharmacotherapeutic possibilities to cope with in this situation are briefly discussed.

Adenosine Triphosphate↗
PubMed1979

[Intermittent claudication. Introduction to clinical diagnosis].

The history and the physical examination are still at the basis of the approach of the patient suffering from intermittent claudication. The history makes clear the specific symptom and its localization. The evolution of the disease, the social and professional handicap are defined. Other troubles and other localizations of the vascular disease are recognized and the nature of the risk factors etablished. The physical examination indicates the pattern and the distribution of the vascular lesions and orientates the pathogenic investigations. A rough assessment of the insufficiency of the cutaneous and muscular circulation is also possible.

Humans↗
PubMed1979

Medical treatment in intermittent claudication.

A variety of measures advocated in the treatment of intermittent claudication are critically reviewed. Daily leg exercises increase the walking ability but the mechanism of this effect remains controversial. To date, doubt persists whether drugs, either vasodilating or antithrombotic, are of any clinical value in this condition.

Exercise Therapy↗
PubMed1988

Double-blind placebo-controlled trial of buflomedil in intermittent claudication.

In a double-blind placebo-controlled trial, buflomedil was shown to cause a significant increase both in median claudication provoking time from 63 sec (range: 24-136 sec) to 124 sec (range: 53-261 sec) (p less than 0.01), and in maximum walking distance (MWD) from 169m (range: 157-308 m) to 293 m (range: 107-429 m) (p less than 0.01). The MWD after three months' buflomedil treatment was also significantly (p = 0.05) prolonged when compared with the MWD in the appropriate placebo group. In contrast, treatment with the placebo caused no significant change in these indices. Subjective improvement was observed in 12 out of 14 patients on buflomedil, whilst it occurred in only 6 out of 14 patients on the placebo (p less than 0.05). The clinical improvement was not associated with an increase in the ankle pressure index or a reduction in platelet aggregation and thromboxane A2 release.

Aged↗
PubMed1988

[Venous pressure in the vertebral venous plexus and its role in cauda equina claudication].

The venous pressure in the ascending lumbar vein was measured by catheter and pressure transducer to document venous stasis in degenerative lumbar spinal canal stenosis. Measurement of the pressure in the ascending lumbar vein at rest revealed a progressive rise of the mean pressure from the control group to the lumbar intervertebral disc herniation group, and the lumbar spinal canal stenosis (LSCS) group in ascending order. Pressure curve tracings showed a plateau accompanying increased abdominal pressure during the Valsalva maneuver. Phase 3 was defined as the recovery period of decreasing pressure which began with the release of abdominal compression and terminated with the return to the initial pressure. The duration of phase 3 was prolonged in LSCS (p less than 0.01). It followed that the prolonged phase 3 documented the existence of venous stasis and its extent in LSCS. It is conceivable that increased venous pressure in the lumbar vertebral venous plexus participates in the pathogenesis of cauda equina claudication in LSCS.

Adolescent↗
PubMed1988

The effects of pentoxifylline on patients with intermittent claudication.

All patients who had intermittent claudication (IC) over an 18-month period were given prescriptions for pentoxifylline (PTFX) 400 mg, three times daily. Patients were required to purchase their medication at a cost of $28 to $35 per month. The drug was administered regardless of the severity of symptoms, and no patient was offered operation without at least a 6-week trial of PTFX. An assessment of the severity of IC was made at the initial visit based on noninvasive data and the impact of the IC on the patient's life-style. One hundred thirty patients were enrolled in the study and were followed for 9 +/- 1 months. Patients were seen every 2 months for treadmill exercise or induced hyperemic testing and interviews until the effects of the medication were determined. The duration of IC before the start of treatment had no effect on the results. IC did not improve in 88 patients (71%) followed for 7.2 +/- 1 month. Thirty-six of these patients stopped the drug themselves because there was no benefit and the expense of PTFX was a hardship. An initial but short-lived improvement in walking was noted in another 13 patients (10%) following 14 +/- 2 months, and the medication was eventually discontinued. Only 23 patients (19%) followed for 11.6 +/- 2 months felt that IC had improved to the point where they did not feel limited in any way. Gastrointestinal symptoms occurred in 13 patients and were severe in eight patients (6%) who stopped taking the medication. The results of PTFX in this group of patients with IC were disappointing at best.(ABSTRACT TRUNCATED AT 250 WORDS)

Drug Evaluation↗
PubMed1986

Captopril in the treatment of hypertension associated with claudication.

The effect of captopril was studied in 40 hypertensive patients (WHO stages I and II) with peripheral vascular disease of the lower limbs (Fontaine stages IIa and IIb). We assessed systolic and diastolic arterial pressure, heart rate in supine and upright position, relative and absolute pain free intervals, and ankle/arm pressure index at rest and after treadmill exercise test. In the first part of the study 20 patients were divided into two groups, one of which was treated with chlorthalidone (25 mg/day) and the other with captopril (50 mg two times a day) for 8 weeks. Statistically significant improvements were only obtained in the captopril-treated group. They concerned the ankle/arm pressure index at rest (P less than 0.05) and after exercise (P less than 0.05) and the absolute pain free interval (P less than 0.05) as well as systolic arterial pressure. Furthermore, 20 more patients were treated with captopril (50 mg two times a day) for 8 weeks, and improvements were found in ankle/arm pressure index at rest (P less than 0.01) and after exercise (P less than 0.001) and in relative and absolute pain free intervals (P less than 0.001) as well as in systolic and diastolic arterial pressure. These results indicate an increase in flow to the limbs of patients with vascular disease treated with captopril, and suggest that captopril is an effective drug without contraindications for the treatment of hypertension associated with claudication.

Blood Pressure↗
PubMed1987

Personality factors as predictors of compliance with and the outcome of supervised self-care program for patients with intermittent claudication.

Personality factors related to the outcome of supervised self-care treatment program were studied in 56 patients with intermittent claudication. Psychological methods used were: structured interviews, the Rorschach Test, the Thematic Apperception Test, Beck's Depression Inventory, the Beth Israel Hospital Inventory of alexithymic behavior and Sauri's Creativity Inventory of psychic flexibility and adaptability. The patients who had no apparent signs of psychic disorders and were also capable of coping with disease-related psychic problems showed the best recovery. Alexithymic patients with a low level of psychic adaptability were likely to find the supportive relationship rewarding, but optimal recovery was not achieved. The results indicated that paranoid tendencies may be obstacles to a satisfying doctor-patient relationship and should be controlled.

Adult↗
PubMed1986

[Neurogenic intermittent claudication--occurrence and causes].

The topic dealt with is about frequency and causes of the neural claudication intermittens among patients of our neurological department as a specific clinical form of lumbosacral disorder syndromes. Concluding special attention is given to diagnostical and therapeutical problems.

Aged↗
PubMed1986

Isokinetic strength and endurance in peripheral arterial insufficiency with intermittent claudication.

Isokinetic plantar flexor peak torques (PT) and contractional work (CW) of the triceps surae muscle have been measured in 24 patients with peripheral arterial insufficiency and intermittent claudication and in 15 controls. Tests were performed both during non-fatiguing (30-180 degrees/s) and fatiguing (200 repeated plantar flexions at 60 degrees/s) conditions. The electromyographic signals (iEMG) from all three heads of the triceps surae were measured. The patients were significantly weaker (PT) and produced significantly less contractional work (CW) than the controls. In contrast, similar iEMGs of the triceps surae heads indicated similar levels of activation. At 40 contractions the majority of the patients had already given up and the remainder showed significantly greater declines in PT (50%) and CW (55%) than did the controls (13% and 18%, respectively). The decline in muscular excitations was similar in both groups. The ratio CW/iEMG showed a dramatic decline in the patients but was virtually constant in the controls. These results indicate a fatigue of low-frequency type in the patient group. There were close correlations between maximum walking tolerance and total work production.

Aged↗
PubMed1986

Giant cell arteritis in a 20-year-old black man: a cause of intermittent calf claudication.

Giant cell arteritis in a young black man is an extremely unusual occurrence. A 20-year-old black man came for treatment of bilateral leg claudication that had been present for a 2-month period. His medical and angiographic evaluation led to an arterial biopsy that demonstrated giant cell arteritis. The patient was treated with corticosteroids and his condition has subsequently improved. Unusual variants of giant cell arteritis are discussed.

Adult↗
PubMed1986

Options in the management of claudication.

Patients who complain of intermittent claudication vary considerably in age, fitness, and in their expectations, and in the distribution of occluded arteries. A careful assessment of all the variables helps the surgeon to choose appropriate treatment from the various options open to him.

Aorta, Abdominal↗
PubMed1987

Differentiation of vascular and neurogenic claudication.

Lower extremity pain caused by exercise but relieved by rest is usually a reliable symptom of chronic arterial insufficiency. However, similar discomfort often occurs in patients who have neurospinal compression. Furthermore, both arterial occlusive disease and neurogenic causes of lower extremity discomfort may present simultaneously. Forty patients with symptoms that suggested intermittent claudication comprised our study group. All had non-arterial cause of their complaint. The nonvascular origin of the symptoms was suggested initially by clinical evaluation in 30 patients and by noninvasive evaluation in 25 patients. The neurospinal origin of symptoms was obscured in 15 patients because of the concomitant presence of significant arterial occlusive disease as demonstrated by noninvasive arterial testing. Twelve of these 15 patients underwent arterial reconstruction, which did not relieve their symptoms. Subsequently, the neurospinal origin of their symptoms was proven by appropriate evaluation and therapy. Forms of evaluation that proved helpful in the differential diagnosis were lumbosacral spine x-rays, electromyography, nerve conduction velocity studies, computerized tomography, Doppler noninvasive assessment and, at times arteriography and contrast myelography.

Adult↗
PubMed1985

[Effects of the Tibetan herbal preparation Padma 28 in intermittent claudication].

In a placebo-controlled double blind study the effect of Padma 28, a Tibetan herbal prescription, on patients with intermittent claudication was investigated. After two weeks without vasoactive therapy 23 patients were treated by Padma 28 and 20 by placebo. The patients had a disease history of at least 8 months, a steady state for symptoms (maximum walking distance below 250 m), and were distributed randomly in the two groups. After 16 weeks the patients treated with Padma 28 exhibited on standardized ergometry an increase of some 100% (p less than 0.01) in the maximum as well as painfree walking distance. The control patients showed increases of 21% in maximum (p less than 0.05 as compared to Padma 28), and 46% in painfree walking distance. The drug was well tolerated and no drop-out ensued because of side effects.

Clinical Trials as Topic↗